For begge studier vises de bivirkninger, som forekom hyppigere hos de ibandronsyrebehandlede patienter i forhold til de placebobehandlede patienter i studie MF 4411.
For both studies, adverse reactions are listed which occurred with a higher incidence in ibandronic acid -treated